HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $53

Benzinga · 04/15 11:07
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $49 to $53.